{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:38:50Z","timestamp":1790303930016,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,25]]},"DOI":"10.7759\/cureus.52952","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T18:59:45Z","timestamp":1706209185000},"source":"Crossref","is-referenced-by-count":7,"title":["Immune Checkpoint Inhibitor-Associated Myocarditis: A Literature Review"],"prefix":"10.7759","author":[{"given":"Rohail","family":"Gul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Shehryar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anber","family":"Mahboob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira K","family":"Kareem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arslan","family":"Inayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danish","family":"Safi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96467-5","article-title":"Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data","volume":"11","author":"Makunts T","year":"2021","unstructured":"Makunts T, Saunders IM, Cohen IV, et al.. Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. Sci Rep. 2021, 11:17324. 10.1038\/s41598-021-96467-5","journal-title":"Sci Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-021-01440-3","article-title":"Immunotherapy-associated cardiotoxicity of immune checkpoint inhibitors and chimeric antigen receptor T cell therapy: diagnostic and management challenges and strategies","volume":"23","author":"Stein-Merlob AF","year":"2021","unstructured":"Stein-Merlob AF, Rothberg MV, Holman P, Yang EH. Immunotherapy-associated cardiotoxicity of immune checkpoint inhibitors and chimeric antigen receptor T cell therapy: diagnostic and management challenges and strategies. Curr Cardiol Rep. 2021, 23:11. 10.1007\/s11886-021-01440-3","journal-title":"Curr Cardiol Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca MP","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem JE, et al.. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019, 140:80-91. 10.1161\/CIRCULATIONAHA.118.034497","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.14744\/AnatolJCardiol.2020.79584","article-title":"Myocarditis associated with immune checkpoint inhibitors: Practical considerations in diagnosis and management","volume":"24","author":"G\u00fcrdo\u011fan M","year":"2020","unstructured":"G\u00fcrdo\u011fan M, Yalta K. Myocarditis associated with immune checkpoint inhibitors: Practical considerations in diagnosis and management. Anatol J Cardiol. 2020, 24:68-75. 10.14744\/AnatolJCardiol.2020.79584","journal-title":"Anatol J Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-021-01442-2","article-title":"A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma","volume":"14","author":"Iwasaki S","year":"2021","unstructured":"Iwasaki S, Hidaka H, Uojima H, et al.. A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma. Clin J Gastroenterol. 2021, 14:1233-9. 10.1007\/s12328-021-01442-2","journal-title":"Clin J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2013.0090","article-title":"Molecular mimicry: its evolution from concept to mechanism as a cause of autoimmune diseases","volume":"33","author":"Oldstone MB","year":"2014","unstructured":"Oldstone MB. Molecular mimicry: its evolution from concept to mechanism as a cause of autoimmune diseases. Monoclon Antib Immunodiagn Immunother. 2014, 33:158-65. 10.1089\/mab.2013.0090","journal-title":"Monoclon Antib Immunodiagn Immunother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling L","year":"2016","unstructured":"Heinzerling L, Ott PA, Hodi FS, et al.. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016, 4:50. 10.1186\/s40425-016-0152-y","journal-title":"J Immunother Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0322-1","article-title":"Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone","volume":"6","author":"Afzal MZ","year":"2018","unstructured":"Afzal MZ, Mabaera R, Shirai K. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone. J Immunother Cancer. 2018, 6:13. 10.1186\/s40425-018-0322-1","journal-title":"J Immunother Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-021-03097-6","article-title":"Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report","volume":"15","author":"Miyauchi Y","year":"2021","unstructured":"Miyauchi Y, Naito H, Tsunemori H, et al.. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report. J Med Case Rep. 2021, 15:508. 10.1186\/s13256-021-03097-6","journal-title":"J Med Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-1284","article-title":"Severe immune-related hepatitis and myocarditis caused by PD-1 inhibitors in the treatment of triple-negative breast cancer: a case report","volume":"10","author":"Yang Y","year":"2022","unstructured":"Yang Y, Wu Q, Chen L, Qian K, Xu X. Severe immune-related hepatitis and myocarditis caused by PD-1 inhibitors in the treatment of triple-negative breast cancer: a case report. Ann Transl Med. 2022, 10:424. 10.21037\/atm-22-1284","journal-title":"Ann Transl Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-2620","article-title":"Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review","volume":"10","author":"Chen Y","year":"2021","unstructured":"Chen Y, Jia Y, Liu Q, et al.. Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review. Ann Palliat Med. 2021, 10:8512-7. 10.21037\/apm-20-2620","journal-title":"Ann Palliat Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003514","article-title":"Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab","volume":"9","author":"Tadokoro T","year":"2016","unstructured":"Tadokoro T, Keshino E, Makiyama A, et al.. Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab. Circ Heart Fail. 2016, 9:e003514. 10.1161\/CIRCHEARTFAILURE.116.003514","journal-title":"Circ Heart Fail"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2018.05.014","article-title":"Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report","volume":"25","author":"Mahmood SS","year":"2018","unstructured":"Mahmood SS, Chen CL, Shapnik N, Krishnan U, Singh HS, Makker V. Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report. Gynecol Oncol Rep. 2018, 25:74-7. 10.1016\/j.gore.2018.05.014","journal-title":"Gynecol Oncol Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211027339","article-title":"Immune-related myocarditis in two patients receiving camrelizumab therapy and document analysis","volume":"28","author":"Zhang C","year":"2022","unstructured":"Zhang C, Qin S, Zuo Z. Immune-related myocarditis in two patients receiving camrelizumab therapy and document analysis. J Oncol Pharm Pract. 2022, 28:1350-6. 10.1177\/10781552211027339","journal-title":"J Oncol Pharm Pract"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-2449","article-title":"Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature","volume":"10","author":"Bi H","year":"2021","unstructured":"Bi H, Ren D, Wang Q, Ding X, Wang H. Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature. Ann Palliat Med. 2021, 10:793-802. 10.21037\/apm-20-2449","journal-title":"Ann Palliat Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.06.025","article-title":"Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung","volume":"99","author":"Semper H","year":"2016","unstructured":"Semper H, Muehlberg F, Schulz-Menger J, Allewelt M, Groh\u00e9 C. Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung. Lung Cancer. 2016, 99:117-9. 10.1016\/j.lungcan.2016.06.025","journal-title":"Lung Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.04.73","article-title":"Successful therapy for autoimmune myocarditis with pembrolizumab treatment for nasopharyngeal carcinoma","volume":"7","author":"Wang Q","year":"2019","unstructured":"Wang Q, Hu B. Successful therapy for autoimmune myocarditis with pembrolizumab treatment for nasopharyngeal carcinoma. Ann Transl Med. 2019, 7:247. 10.21037\/atm.2019.04.73","journal-title":"Ann Transl Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.806","article-title":"Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia","volume":"19","author":"Berg DD","year":"2017","unstructured":"Berg DD, Vaduganathan M, Nohria A, Davids MS, Alyea EP, Torre M, Padera RF Jr. Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. Eur J Heart Fail. 2017, 19:682-5. 10.1002\/ejhf.806","journal-title":"Eur J Heart Fail"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2017.1401079","article-title":"Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma","volume":"56","author":"Chen Q","year":"2018","unstructured":"Chen Q, Huang DS, Zhang LW, Li YQ, Wang HW, Liu HB. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma. Clin Toxicol (Phila). 2018, 56:667-71. 10.1080\/15563650.2017.1401079","journal-title":"Clin Toxicol (Phila)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"L\u00e4ubli H","year":"2015","unstructured":"L\u00e4ubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015, 3:11. 10.1186\/s40425-015-0057-1","journal-title":"J Immunother Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson DB","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al.. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016, 375:1749-55. 10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas N","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020, 9:e013757. 10.1161\/JAHA.119.013757","journal-title":"J Am Heart Assoc"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.14740\/cr1319","article-title":"Clinical characteristics and outcomes in immune checkpoint inhibitor therapy-associated myocarditis","volume":"12","author":"Thakker RA","year":"2021","unstructured":"Thakker RA, Lee MA, Albaeni A, et al.. Clinical characteristics and outcomes in immune checkpoint inhibitor therapy-associated myocarditis. Cardiol Res. 2021, 12:270-8. 10.14740\/cr1319","journal-title":"Cardiol Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu JR","year":"2019","unstructured":"Hu JR, Florido R, Lipson EJ, et al.. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019, 115:854-68. 10.1093\/cvr\/cvz026","journal-title":"Cardiovasc Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2019.100420","article-title":"Cardiotoxicity from immune checkpoint inhibitors","volume":"25","author":"Michel L","year":"2019","unstructured":"Michel L, Rassaf T, Totzeck M. Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc. 2019, 25:100420. 10.1016\/j.ijcha.2019.100420","journal-title":"Int J Cardiol Heart Vasc"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2218-6751.2015.06.06","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid J","year":"2015","unstructured":"Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015, 4:560-75. 10.3978\/j.issn.2218-6751.2015.06.06","journal-title":"Transl Lung Cancer Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen JB","year":"2017","unstructured":"Haanen JB, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017, 28:iv119-42. 10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat S","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, et al.. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016, 27:559-74. 10.1093\/annonc\/mdv623","journal-title":"Ann Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267572","article-title":"Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events","volume":"17","author":"Kawahira M","year":"2022","unstructured":"Kawahira M, Kanmura S, Mizuno K, et al.. Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events. PLoS One. 2022, 17:e0267572. 10.1371\/journal.pone.0267572","journal-title":"PLoS One"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille C","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M, et al.. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020, 6:865-71. 10.1001\/jamaoncol.2020.0726","journal-title":"JAMA Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100309","article-title":"Heterogeneous outcomes of immune checkpoint inhibitor rechallenge in patients with NSCLC: a systematic review and meta-analysis","volume":"3","author":"Xu S","year":"2022","unstructured":"Xu S, Shukuya T, Tamura J, et al.. Heterogeneous outcomes of immune checkpoint inhibitor rechallenge in patients with NSCLC: a systematic review and meta-analysis. JTO Clin Res Rep. 2022, 3:100309. 10.1016\/j.jtocrr.2022.100309","journal-title":"JTO Clin Res Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/169834-immune-checkpoint-inhibitor-associated-myocarditis-a-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T15:13:55Z","timestamp":1707491635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/169834-immune-checkpoint-inhibitor-associated-myocarditis-a-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.52952","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,25]]}}}